Regulation of collagen-derived antiangiogenic factors by p53

Expert Opinion on Biological Therapy

Volumn 8, Issue 7, 2008, Pages 941-950

  Assadian, Sarah ^a   Teodoro, Jose G ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Angiogenic switch; Antiangiogenic therapy; Collagen; Endostatin; In situ tumors; p53 tumor suppressor protein; Tumstatin

Indexed keywords

ANTINEOPLASTIC AGENT; ARRESTEN; BEVACIZUMAB; CANSTATIN; COLLAGEN DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; ENDOSTATIN; PROTEIN P53; RESTIN; TUMSTATIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ARRESTIN; AUTOANTIGENS; COLLAGEN; COLLAGEN TYPE IV; ENDOSTATINS; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 47549113129     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.7.941     Document Type: Review

References (86)

1. Gabellini C, Del Bufalo D, Zupi G. Involvement of RB gene family in tumor angiogenesis. Oncogene 2006;25:5326-32
2. Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-25
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10
5. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29
6. Carr AM. Cell cycle. Piecing together the p53 puzzle. Science 2000;287:1765-6
7. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9
8. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31
9. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6
10. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604
11. Holmgren L, Jackson G, Arbiser J. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 1998;17:819-24 • In this paper it is demonstrated that the p53 tumor suppressor can maintain tumours in a dormant state by inhibiting angiogenesis.
12. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000;14:34-44 • The first demonstration, to our knowledge, that p53 can interfere with angiogenesis through the hypoxia inducible factor.
13. Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by Transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655-61
14. Sherif ZA, Nakai S, Pirollo KF, et al. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 2001;8:771-82
15. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4 • The first ever demonstration, to our knowledge, of an anti-angiogenic factor upregulated by p53.
16. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007;85:1175-86
17. Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313:968-71 •• Demonstration of a genetic and biochemical link between p53 and CDAFs.
18. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-33
19. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem 1995;64:403-34
20. Nissi R, Autio-Harmainen H, Marttila P, et al. Prolyl 4-hydroxylase isoenzymes I and II have different expression patterns in several human tissues. J Histochem Cytochem 2001;49:1143-53
21. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992;27:93-127
22. Colorado PC, Torre A, Kamphaus G, et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000;60:2520-6
23. Pozzi A, Wary KK, Giancotti FG, Gardner HA. Integrin α1β1 mediates a unique collagen-dependent proliferation pathway in vivo. J Cell Biol 1998;142:587-94
24. Bloch W, Forsberg E, Lentini S, et al. β1 integrin is essential for teratoma growth and angiogenesis. J Cell Biol 1997;139:265-78
25. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000;275:1209-15
26. Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000;275:8051-61
27. Magnon C, Galaup A, Mullan B, et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins. Cancer Res 2005;65:4353-61
28. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003;278:37632-6
29. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000;275:21340-8
30. Maeshima Y, Yerramalla UL, Dhanabal M, et al. Extracellular matrix-derived peptide binds to α(b)β(3) integrin and inhibits angiogenesis. J Biol Chem 2001;276:31959-68
31. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002;295:140-3 • Characterization of the mechanism by which Tumstatin specifically inhibits endothelial cell growth.
32. Han J, Ohno N, Pasco S, et al. A cell binding domain from the α3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem 1997;272:20395-401
33. Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000;275:23745-50
34. Pasco S, Ramont L, Maquart FX, Monboisse JC. Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol 2004;49:221-33
35. Shahan TA, Ziaie Z, Pasco S, et al. Identification of CD47/integrin-associated protein and α(v)β3 as two receptors for the α3(IV) chain of type IV collagen on tumor cells. Cancer Res 1999;59:4584-90
36. Kawaguchi T, Yamashita Y, Kanamori M, et al. The PTEN/Akt pathway dictates the direct αVβ3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 2006;66:11331-40
37. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore. Curr Opin Cell Biol 2001;13:534-40
38. Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin. Cancer Cell 2003;3:589-601 • A demonstration that proteolytic processing of collagen IV alpha3 by MMP-9 can have significant effects on angiogenesis in vivo.
39. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85 •• The first characterization, to our knowledge, of endostatin as an antiangiogenic factor.
40. Wen W, Moses MA, Wiederschain D, et al. The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052-6
41. Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000;19:1187-94
42. Sasaki T, Hohenester E, Timpl R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life 2002;53:77-84
43. Dixelius J, Cross M, Matsumoto T, et al. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 2002;62:1944-7
44. Dhanabal M, Volk R, Ramchandran R, et al. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999;258:345-52
45. Sudhakar A, Sugimoto H, Yang C, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αbβ3 and α5β1 integrins. Proc Natl Acad Sci USA 2003;100:4766-71
46. Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002;277:27872-9
47. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63
48. Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007;110:2899-906 • This paper describes how endostatin specifically inhibits proliferating endothelial cells.
49. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999;13:1911-22
50. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-3
51. Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002;519:147-52
52. Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003;278:22404-11
53. Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999;255:735-9
54. Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000;301:1179-90
55. Miled C, Pontoglio M, Garbay S, et al. A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. Cancer Res 2005;65:5096-104
56. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;124:207-19
57. Form DM, Pratt BM, Madri JA. Endothelial cell proliferation during angiogenesis. In vitro modulation by basement membrane components. Lab Invest 1986;55:521-30
58. Herbst TJ, McCarthy JB, Tsilibary EC, Furcht LT. Differential effects of laminin, intact type IV collagen, and specific domains of type IV collagen on endothelial cell adhesion and migration. J Cell Biol 1988;106:1365-73
59. Furcht LT. Role of cell adhesion molecules in promoting migration of normal and malignant cells. Prog Clin Biol Res 1984;149:15-53
60. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988;59:44-51
61. Haralabopoulos GC, Grant DS, Kleinman HK, et al. Inhibitors of basement membrane collagen synthesis prevent endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. Lab Invest 1994;71:575-82
62. Maragoudakis ME, Haralabopoulos GC, Tsopanoglou NE, Pipili-Syneros E. Validation of collagenous protein synthesis as an index for angiogenesis with the use of morphological methods. Microvasc Res 1995;50:215-22
63. Maragoudakis ME, Missirlis E, Karakiulakis GD, et al. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties. Kidney Int 1993;43:147-50
64. Oberbaumer I, Wiedemann H, Timpl R, Kuhn K. Shape and assembly of type IV procollagen obtained from cell culture. Embo J 1982;1:805-10
65. Grant DS, Kibbey MC, Kinsella JL, et al. The role of basement membrane in angiogenesis and tumor growth. Pathol Res Pract 1994;190:854-63
66. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-8
67. Flannery CR. MMPs and ADAMTSs: functional studies. Front Biosci 2006;11:544-69
68. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002;359:1019-25
69. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787
70. Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet 2001;9:811-4
71. Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005;102:2934-9 •• Evidence is presented showing that even modest increases in CDAF serum levels can significantly slow tumor growth in vivo.
72. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43
73. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985;56:531-8
74. Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9
75. Folkman J, Long DM Jr, Becker FF. Growth and metastasis of tumor in organ culture. Cancer 1963;16:453-67
76. Gautam A, Densmore CL, Melton S, et al. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002;9:28-36
77. Kaminski JM, Shinohara E, Summers JB, et al. The controversial abscopal effect. Cancer Treat Rev 2005;31:159-72
78. Camphausen K, Moses MA, Menard C, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 2003;63:1990-3 • Evidence is presented that soluble factors produced in a p53-dependent mechanism may be involved in long-range effects that inhibit tumor growth.
79. Hartford AC, Gohongi T, Fukumura D, Jain RK. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. Cancer Res 2000;60:2128-31
80. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28
81. Sckell A, Safabakhsh N, Dellian M, Jain RK. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. Cancer Res 1998;58:5866-9
82. Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991;51:2-4
83. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86
84. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8
85. Giuriato S, Ryeom S, Fan AC, et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006;103:16266-71
86. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-30